LFST
Bearish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
LifeStance Health Group, Inc.
- Nom
- LifeStance Health Group, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NASDAQ
- Capitalisation
- $4.9B
- Employés
- 8,542
- PDG
- David Patrick Bourdon
- Site web
- https://www.lifestance.com
- Marché
- ACHCBTSGHIMSLFMDPRVAUHS
LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network. The company offers a comprehensive array of mental health solutions, encompassing psychiatric evaluations and treatment, specialized psychological and neuropsychological testing, and diverse therapeutic modalities including individual, family, and group therapy sessions. The organization addresses a wide spectrum of mental health conditions, ranging from common issues like anxiety and depression to more complex challenges such as bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. Patients have access to care through various channels: virtually via its online platform or in-person at its many centers located throughout 32 states. LifeStance is dedicated to supporting individuals across all age groups, providing care for children, adolescents, adults, and the elderly. LifeStance Health Group, Inc. was founded in 2017 and its main offices are situated in Scottsdale, Arizona.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 527 941 titres (~6 100 093,43 $ US)
- Insiders
- DeLuca TeresaBurdick Kenneth A
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$7,643,016
Avg sell (VWAP, 90d window) $11.54 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,001,520 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | Paunovich Vukasin | Sell · S | 42,067 | $12.87 | $541,402 | Form 4 |
| 2026-08-14 | DeLuca Teresa | Sell · S | 7,500 | $12.68 | $95,100 | Form 4 |
| 2026-08-13 | DeLuca Teresa | Sell · S | 20,441 | $12.23 | $249,993 | Form 4 |
| 2026-08-11 | Burdick Kenneth A | Sell · S | 500,000 | $11.51 | $5,755,000 | Form 4 |
| 2026-08-10 | Miller Lisa K | Sell · S · 10b5-1 | 47,912 | $10.85 | $519,845 | Form 4 |
| 2026-08-10 | Paunovich Vukasin | Sell · S · 10b5-1 | 44,394 | $10.85 | $481,675 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
LFST presents a compelling turnaround story with strong liquidity (80) and improving fundamentals (75), supported by a Q2 2026 earnings beat and a BTIG price target upgrade pushing the stock to new 52-week highs.
The first sentence of the analysis written for LFST on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.65 · operating margin 1.7%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 32.4% | 32.2% | 28.6% | 27.6% | 30.2% | |
| Ebit Margin | 1.7% | -2.5% | -17.6% | -24.8% | -44.1% | |
| Ebitda Margin | 5.5% | 3.2% | -9.9% | -16.7% | -36.0% | |
| Operating Profit Margin | 1.7% | -2.5% | -17.9% | -24.5% | -42.9% | |
| Pretax Profit Margin | 0.9% | -4.6% | -19.6% | -27.1% | -49.9% | |
| Continuous Operations Profit Margin | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | |
| Net Profit Margin | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | |
| Bottom Line Profit Margin | 0.7% | -4.6% | -17.6% | -25.1% | -51.5% | |
| Current Ratio | 1.652 | 1.365 | 1.113 | 1.325 | 2.283 | |
| Quick Ratio | 1.652 | 1.365 | 1.113 | 1.325 | 1.957 | |
| Solvency Ratio | 0.094 | 0.020 | -0.155 | -0.223 | -0.662 | |
| Cash Ratio | 0.987 | 0.675 | 0.389 | 0.617 | 1.268 | |
| Price To Earnings Ratio | 234.667 | -49.133 | -15.353 | -8.098 | -9.067 | |
| Price To Earnings Growth Ratio | -1.956 | 0.696 | 0.937 | 0.193 | -0.342 | |
| Forward Price To Earnings Growth Ratio | -1.956 | 0.696 | 0.937 | 0.193 | -0.342 | |
| Price To Earnings Diluted Ratio | 352.000 | -49.133 | -15.353 | -8.098 | -9.067 | |
| Price To Earnings Diluted Growth Ratio | -3.106 | 0.696 | 0.937 | 0.193 | -0.342 | |
| Price To Book Ratio | 1.787 | 1.932 | 2.014 | 1.156 | 2.018 | |
| Price To Sales Ratio | 1.908 | 2.234 | 2.725 | 2.042 | 4.671 | |
| Price To Free Cash Flow Ratio | 24.699 | 32.608 | -50.122 | -66.314 | -36.652 | |
| Price To Operating Cash Flow Ratio | 18.594 | 26.052 | -170.409 | 33.247 | 331.000 | |
| Debt To Assets Ratio | 0.088 | 0.229 | 0.242 | 0.220 | 0.082 | |
| Debt To Equity Ratio | 0.128 | 0.335 | 0.358 | 0.315 | 0.103 | |
| Debt To Capital Ratio | 0.113 | 0.251 | 0.263 | 0.240 | 0.093 | |
| Long Term Debt To Capital Ratio | 0.089 | 0.162 | 0.164 | 0.129 | 0.092 | |
| Financial Leverage Ratio | 1.449 | 1.465 | 1.477 | 1.431 | 1.247 | |
| Working Capital Turnover Ratio | 11.493 | 23.496 | 26.365 | 8.305 | 8.893 | |
| Operating Cash Flow Ratio | 0.580 | 0.469 | -0.083 | 0.300 | 0.081 | |
| Operating Cash Flow Sales Ratio | 0.103 | 0.086 | -0.016 | 0.061 | 0.014 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.753 | 0.799 | 3.400 | -0.501 | -9.031 | |
| Debt Service Coverage Ratio | 1.330 | 1.185 | -3.504 | -5.677 | -5.323 | |
| Interest Coverage Ratio | 2.071 | -1.191 | -8.913 | -10.547 | -7.359 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.209 | 14.794 | -5.772 | 22.511 | 7.120 | |
| Operating Cash Flow Coverage Ratio | 0.753 | 0.221 | -0.033 | 0.110 | 0.059 | |
| Capital Expenditure Coverage Ratio | 4.046 | 4.974 | -0.417 | 0.666 | 0.100 | |
| Dividend Paid And Capex Coverage Ratio | 4.046 | 4.974 | -0.417 | 0.666 | 0.100 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.804 | 78.374 | -31.540 | -14.800 | -13.033 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 32.4% | ▲0.2% | ▲2.2% |
| Ebit Margin | 1.7% | ▲4.2% | ▲19.1% |
| Ebitda Margin | 5.5% | ▲2.3% | ▲16.3% |
| Operating Profit Margin | 1.7% | ▲4.2% | ▲18.9% |
| Pretax Profit Margin | 0.9% | ▲5.5% | ▲20.9% |
| Continuous Operations Profit Margin | 0.7% | ▲5.3% | ▲19.2% |
| Net Profit Margin | 0.7% | ▲5.3% | ▲19.2% |
| Bottom Line Profit Margin | 0.7% | ▲5.3% | ▲20.3% |
| Current Ratio | 1.652 | ▲0.286 | ▲0.104 |
| Quick Ratio | 1.652 | ▲0.286 | ▲0.170 |
| Solvency Ratio | 0.094 | ▲0.074 | ▲0.280 |
| Cash Ratio | 0.987 | ▲0.311 | ▲0.200 |
| Price To Earnings Ratio | 234.667 | ▲283.800 | ▲204.064 |
| Price To Earnings Growth Ratio | -1.956 | ▼-2.652 | ▼-1.861 |
| Forward Price To Earnings Growth Ratio | -1.956 | ▼-2.652 | ▼-1.861 |
| Price To Earnings Diluted Ratio | 352.000 | ▲401.133 | ▲297.930 |
| Price To Earnings Diluted Growth Ratio | -3.106 | ▼-3.802 | ▼-2.781 |
| Price To Book Ratio | 1.787 | ▼-0.145 | ▲0.005 |
| Price To Sales Ratio | 1.908 | ▼-0.326 | ▼-0.808 |
| Price To Free Cash Flow Ratio | 24.699 | ▼-7.909 | ▲43.855 |
| Price To Operating Cash Flow Ratio | 18.594 | ▼-7.458 | ▼-29.103 |
| Debt To Assets Ratio | 0.088 | ▼-0.141 | ▼-0.084 |
| Debt To Equity Ratio | 0.128 | ▼-0.208 | ▼-0.120 |
| Debt To Capital Ratio | 0.113 | ▼-0.138 | ▼-0.079 |
| Long Term Debt To Capital Ratio | 0.089 | ▼-0.073 | ▼-0.038 |
| Financial Leverage Ratio | 1.449 | ▼-0.016 | ▲0.035 |
| Working Capital Turnover Ratio | 11.493 | ▼-12.004 | ▼-4.218 |
| Operating Cash Flow Ratio | 0.580 | ▲0.111 | ▲0.311 |
| Operating Cash Flow Sales Ratio | 0.103 | ▲0.017 | ▲0.053 |
| Free Cash Flow Operating Cash Flow Ratio | 0.753 | ▼-0.046 | ▲1.669 |
| Debt Service Coverage Ratio | 1.330 | ▲0.145 | ▲3.728 |
| Interest Coverage Ratio | 2.071 | ▲3.262 | ▲7.259 |
| Short Term Operating Cash Flow Coverage Ratio | 3.209 | ▼-11.585 | ▼-5.163 |
| Operating Cash Flow Coverage Ratio | 0.753 | ▲0.532 | ▲0.531 |
| Capital Expenditure Coverage Ratio | 4.046 | ▼-0.928 | ▲2.172 |
| Dividend Paid And Capex Coverage Ratio | 4.046 | ▼-0.928 | ▲2.172 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.804 | ▼-44.570 | ▲23.243 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.72B | $2.79B | $2.88B | $1.76B | $3.12B | |
| Enterprise value | $2.66B | $3.12B | $3.31B | $2.13B | $3.13B | |
| EV / Sales | 1.87x | 2.50x | 3.13x | 2.47x | 4.69x | |
| EV / Op. cash flow | 18.22x | 29.13x | -196.01x | 40.26x | 332.14x | |
| EV / Free cash flow | 24.20x | 36.47x | -57.65x | -80.30x | -36.78x | |
| EV / EBITDA | 33.80x | 78.37x | -31.54x | -14.80x | -13.03x | |
| Net debt / EBITDA | -0.69x | 8.29x | -4.12x | -2.58x | -0.04x | |
| Current ratio | 1.65x | 1.36x | 1.11x | 1.32x | 2.28x | |
| Income quality | 15.12x | -1.87x | 0.09x | -0.24x | -0.03x | |
| Graham number | $1 | — | — | — | — | |
| Graham net-net | -$1 | -$1 | -$1 | -$1 | -$0 | |
| Tax burden | 78.2% | 99.7% | 90.2% | 92.6% | 92.2% | |
| Interest burden | 51.5% | 185.4% | 111.4% | 109.4% | 113.2% | |
| Working capital | $164.2M | $83.6M | $22.9M | $57.2M | $149.8M | |
| Invested capital | $1.95B | $1.88B | $1.90B | $1.99B | $1.81B | |
| Return on assets | 0.4% | -2.7% | -8.8% | -9.9% | -15.9% | |
| Operating ROA | 1.1% | -1.5% | -8.8% | -10.2% | -16.4% | |
| Return on tangible assets | 1.3% | -9.1% | -31.3% | -33.8% | -72.8% | |
| Return on equity | 0.6% | -4.0% | -13.0% | -14.2% | -19.9% | |
| Return on invested capital | 0.9% | -1.6% | -8.7% | -9.5% | -14.6% | |
| Return on capital employed | 1.2% | -1.7% | -9.9% | -10.5% | -15.8% | |
| Earnings yield | 0.4% | -2.1% | -6.5% | -12.3% | -9.9% | |
| Free cash flow yield | 4.0% | 3.1% | -2.0% | -1.5% | -2.7% | |
| Capex / Op. cash flow | 24.7% | 20.1% | -240.0% | 150.1% | 1003.1% | |
| Capex / Depreciation | 66.0% | 30.4% | 50.4% | 114.5% | 174.5% | |
| Capex / Sales | 2.5% | 1.7% | 3.8% | 9.2% | 14.2% | |
| SG&A / Sales | 26.8% | 29.0% | 38.9% | 44.0% | 65.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 5.2% | 6.1% | 9.4% | 21.8% | 38.9% | |
| Intangibles / Total assets | 66.7% | 70.1% | 71.8% | 70.7% | 78.1% | |
| Days sales outstanding | 25d | 39d | 43d | 43d | 54d | |
| Days payables outstanding | 2d | 3d | 11d | 14d | 11d | |
| Operating cycle | 25d | 39d | 43d | 43d | 84d | |
| Cash conversion cycle | 22d | 35d | 32d | 29d | 73d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-13 LifeStance Health Group (LFST) Is Up 3.44% in One Week: What You Should Know Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-12 5 Low-Leverage Stocks to Buy as High Oil Prices Shake Investor Confidence High oil prices and market volatility spotlight five low-leverage stocks with strong earnings growth and resilient balance sheets.
- 2026-08-11 LifeStance Health (LFST) Upgraded to Buy: Here''s Why LifeStance Health (LFST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-08-11 LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out? LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-08-11 LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care One in Three Women Don''t Know Perimenopause Can Cause Anxiety, Depression and Mood Changes; Majority Who Seek Mental Healthcare Find It Helpful SCOTTSDALE, Ariz., Aug. 11, 2026 /PRNewswire/ -- A LifeStance Health survey of 1,000 women experiencing perimenopause or menopause released today reveals this life stage carries an unexpected mental health toll, as one in three women (33%) report being unaware that perimenopause can cause mental health-related symptoms.
- 2026-08-11 LifeStance Health Group (NASDAQ:LFST) Sets New 1-Year High After Analyst Upgrade LifeStance Health Group, Inc. (NASDAQ: LFST - Get Free Report)''s stock price reached a new 52-week high during trading on Monday after BTIG Research raised their price target on the stock from $15.00 to $16.00. BTIG Research currently has a buy rating on the stock. LifeStance Health Group traded as high as $12.06 and last traded
- 2026-08-06 LifeStance Health Group Q2 Earnings Call Highlights LifeStance Health Group NASDAQ: LFST reported second-quarter results that exceeded its prior expectations, driven by higher visit volumes, increased revenue per visit and continued clinician productivity gains. The outpatient mental health provider raised its full-year revenue, Center Margin and adjusted EBITDA guidance.
- 2026-08-06 LifeStance Health Group, Inc. (LFST) Q2 2026 Earnings Call Transcript LifeStance Health Group, Inc. (LFST) Q2 2026 Earnings Call Transcript
- 2026-08-06 LifeStance Health Group (LFST) Tops Q2 Earnings and Revenue Estimates LifeStance Health Group (LFST) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.01 per share a year ago.
- 2026-08-06 LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation''s largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2026.